RxDoctor Payments Data

Nicholas Ksenich, MD

Family Medicine · Elyria, OHNPI 1952513277

Payments from drug & device makers

$12,160in general payments, 2019–2025

Across 793 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$840
  • Merck$823
  • Lilly USA, LLC$746
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$12,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,160 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$79,950
Medicare patients
237
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$84,166
JanuviaSitagliptin Phosphate54$65,939
EliquisApixaban54$57,951
RybelsusSemaglutide31$53,263
OzempicSemaglutide34$40,608
MounjaroTirzepatide32$39,477
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,266
Breo ElliptaFluticasone/Vilanterol36$27,709
FarxigaDapagliflozin Propanediol18$24,146
RexultiBrexpiprazole17$23,898
Nurtec OdtRimegepant Sulfate18$23,887
MyrbetriqMirabegron17$19,954
XareltoRivaroxaban14$16,890
KerendiaFinerenone11$11,277
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,182$93,87165 claims
Boehringer IngelheimJardiance, Stiolto Respimat$300$91,08175 claims
PfizerEliquis, Nurtec Odt$840$81,83872 claims
MerckJanuvia$823$65,93954 claims
GSKTrelegy Ellipta, Breo Ellipta$698$56,97571 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,191$39,79256 claims
Lilly USA, LLCMounjaro$746$39,47732 claims
Otsuka America Pharmaceutical, Inc.Rexulti$280$23,89817 claims
Astellas Pharma US IncMyrbetriq$279$19,95417 claims
Johnson & JohnsonXarelto$514$16,89014 claims
BayerKerendia$181$11,27711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$185$6,78214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Elyria

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →